A304360 Stock Overview
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
S.Biomedics CO., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩33,050.00 |
| 52 Week High | ₩49,500.00 |
| 52 Week Low | ₩6,950.00 |
| Beta | 0 |
| 1 Month Change | 190.93% |
| 3 Month Change | 293.92% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| A304360 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -15.3% | 1.9% | 2.2% |
| 1Y | n/a | 6.5% | 5.4% |
Return vs Industry: Insufficient data to determine how A304360 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A304360 performed against the KR Market.
Price Volatility
| A304360 volatility | |
|---|---|
| A304360 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A304360's share price has been volatile over the past 3 months.
Volatility Over Time: A304360's weekly volatility has increased from 14% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 54 | n/a | www.sbiomedics.com |
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; and Cureskin Inj for the treatment of depressed acne scar and is in phase III clinical trial and marketing. The company also provides testing services; and owns platform technologies for developing cell therapy products.
S.Biomedics CO., LTD. Fundamentals Summary
| A304360 fundamental statistics | |
|---|---|
| Market cap | ₩376.74b |
| Earnings (TTM) | -₩7.52b |
| Revenue (TTM) | ₩13.11b |
28.7x
P/S Ratio-50.1x
P/E RatioIs A304360 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A304360 income statement (TTM) | |
|---|---|
| Revenue | ₩13.11b |
| Cost of Revenue | ₩6.55b |
| Gross Profit | ₩6.55b |
| Other Expenses | ₩14.08b |
| Earnings | -₩7.52b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -660.01 |
| Gross Margin | 50.00% |
| Net Profit Margin | -57.40% |
| Debt/Equity Ratio | 84.4% |
How did A304360 perform over the long term?
See historical performance and comparison